EOE Experts Medical Advisory Board

The Medical Advisory Board (MAB) is comprised of leading experts from a range of oncology subspecialties. MAB members actively contribute to the course content and the interactive Grand Rounds sessions.

Andrew D. Seidman, MD

Attending Physician for the Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, and a Professor of Medicine, Weill Cornell Medical College. Dr. Seidman is the recipient of a Career Development Award from the American Society of Clinical Oncology (ASCO) for his research on the role of the taxanes in breast cancer treatment and Past President of the American Society of Breast Disease.

Debu Tripathy, MD

Professor of Medicine and Co-Leader of the Women's Cancer Program at USC Norris Comprehensive Cancer Center. His area of clinical research interest is novel therapeutics in breast cancer, specifically, growth factor receptor pathway targeting as well as biomarkers that predict sensitivity and resistance. Dr. Tripathy has published numerous original laboratory and clinical research articles in the area of breast cancer and serves on several editorial boards, study sections and societies. He has served as the President of the American Society of Breast Disease and the Society of Integrative Oncology.

John M. Kirkwood, MD

Director of the Melanoma and Skin Cancer Program at the University of Pittsburgh Cancer Institute and Professor at the University of Pittsburgh School of Medicine. He has received international acclaim for leading a multicenter study developed on the basis of his pioneering work with biological treatments for melanoma that has provided the first adjuvant, or additional, therapy for treating patients with high-risk melanoma, a type likely to recur despite surgery.

John L. Marshall, MD

Chief, Hematology and Oncology Lombardi Comprehensive Cancer Center Georgetown University. An internationally recognized expert in new drug development for GI cancer, with expertise in phase I, II, and III trial design, and has served as Principal Investigator for more than one hundred clinical trials. Established the Otto J Ruesch Center for the Cure of GI Cancers.

Michael Morse, MD

Professor of Medicine in the Division of Medical Oncology at Duke University Medical Center, Durham, NC. Clinical expertise includes management of gastrointestinal malignancies and melanoma and his research expertise includes the development of targeted therapies including immunotherapies for cancer. He has published extensively and a national speaker on topics in cancer immunotherapy, targeted therapies, and gastrointestinal malignancies, including textbooks on Cancer Vaccines and Liver Tumors.

Sergio Giralt, MD

Chief, Adult Bone Marrow Transplant Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center. Dr. Giralt is a member of the International Bone Marrow Transplant Registry Executive Committee, Past Chair of the Blood and Marrow Transplant Clinical Trials Network and President-Elect of the American Society for Blood and Marrow Transplantation.

Charles A. Schiffer, MD

Professor of Medicine and Oncology at Wayne State University School of Medicine and the Karmanos Cancer Institute in Detroit, Michigan where he is the director of the Leukemia/Lymphoma Multidisciplinary Program. In 2006, Dr. Schiffer received the Dr. John J. Kenney Award from the Leukemia/Lymphoma Society of America. He has served on the Editorial Boards for Blood, the Journal of Clinical Oncology, International Journal of Hematology, Transfusion Medicine Reviews and Transfusion and has served as Chairman of both the Leukemia Committee of the Cancer and Leukemia Group B and the FDA Oncologic Drug Advisory Committee.

Martin Tallman, MD

Chief, Leukemia Service at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College in New York. Dr. Tallman has contributed a large body of work to the literature addressing the diagnosis, biology, and treatment of acute leukemia and other hematologic malignancies. Dr. Tallman serves on the Acute Myeloid Leukemia, Chronic Myeloid Leukemia and Myelodysplastic Syndrome Committees of the National Comprehensive Cancer Network (NCCN). He also serves on the editorial boards of a variety of scientific journals, including Leukemia Research, Cancer Clinical Cytometry, Evidence-Based Oncology, Blood Reviews, Annuals of Hematology, and the Hematology Journal.

Andrew Zelentz, MD, PhD

Vice Chair, Medical Informatics, Department of Medicine Memorial Sloan Kettering Cancer Center. Former Chief of MSK's Lymphoma Service and chairperson of the Non-Hodgkin Lymphoma Guidelines panel of the National Comprehensive Cancer Network and vice chairperson of the Lymphoma Core Committee of the Cancer and Leukemia Group B. Published more than 100 papers on lymphoma research in journals such as Blood, Journal of Clinical Oncology, and Clinical Cancer Research.

Thomas Herzog, MD

Director of Gynecologic Oncology and the Physicians & Surgeons Endowed Professor of Clinical Gynecology and Obstetrics, Columbia University. Served as a Principal Investigator in a number of GOG trials with a special emphasis in ovarian and endometrial cancers. Dr. Herzog has authored or co-authored over 185 peer-reviewed articles and lectures extensively. He serves on the editorial boards of Gynecologic Oncology, Obstetrics and Gynecology International, Hematology Oncology Times, and others.

William P. McGuire, MD

Medical Director of The Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center in Baltimore, Maryland. Clinical Professor of Medicine and Oncology at Georgetown University's Lombardi Comprehensive Cancer Center. Dr. McGuire's research interests include gynecologic oncology, experimental therapeutics, and cancer management. Dr. McGuire is actively involved in a number of professional societies, including the Gynecologic Oncology Group, the American College of Obstetricians and Gynecologists, and is a member of the Gynecologic Cancer Advisory Committee for the American Cancer Society's National Office.

Paul A. Bunn, Jr., MD

James Dudley Chair in Cancer Research, Professor of Medical Oncology, University of Colorado Cancer Center. Research interests focus on novel therapies for lung cancer. He has published more than 300 articles in peer-reviewed journals, 122 reviews and 90 book chapters on lung cancer. Dr. Bunn's studies have set standards for the treatment of lung cancer, have identified issues of natural history and have identified biomarkers for prognosis and therapy selection.

E. Roy Berger, MD

Assistant Clinical Professor of Medicine, SUNY Stony Brook College of Medicine Stony Brook, NY. Medical Oncologist with over 30 years of experience in the diagnosis and treatment of solid tumors, hematologic malignancies and supportive care. Founding member of the Prostate Cancer Education Council, a group that sponsors free prostate cancer screenings nationally. In addition, he serves on the medical advisory boards of two of the largest patient advocacy groups in the US for patients with prostate cancer. Authored over 50 peer reviewed articles and participated in 100 clinical trials.

E. David Crawford, MD

Distinguished Professor of Surgery, Urology, and Radiation Oncology, the Head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus. Internationally-recognized expert in benign prostate hypertrophy, urologic cancers, and, in particular, prostate cancer. The recipient of more than 69 research grants, he has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone refractory prostate cancer, and other areas of urological infections and malignancies.

Daniel P. Petrylak, MD

Daniel leads the Genitourinary Cancers Medical Oncology team at Yale Cancer Center and Smilow Cancer Hospital. Director of the Prostate Cancer Research Group and co-director of the Signal Transduction Research Program. Currently serves as the Principal Investigator or co-Principal Investigator on 7 Southwest Oncology Group (SWOG) clinical trials for genitourinary cancers. He also heads the Advanced Bladder Cancer Subcommittee for SWOG.

Neal D. Shore, MD

Medical Director of the Carolina Urologic Research Center. Has conducted more than 100 clinical trials, focusing mainly on prostate and bladder disease. Certified Physician Investigator with numerous publications in peer-reviewed journals and extensive experience lecturing on the treatment of prostate cancer and prostate enlargement.

Thomas E. Hutson, DO

Director of the Genitourinary Oncology Program and Co-Director of the Center of Excellence for Texas Oncology in the Charles A. Sammons Cancer Center at Baylor University Medical Center; and Co-Chair of Genitourinary Research for US Oncology. Professor of Medicine at Texas A&M Health Science Center College of Medicine.

Ronald Bukowski, MD

Emeritus staff at the Cleveland Clinic Foundation, and Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University. He was recently the Deputy Director of the Cleveland Clinic Taussig Cancer Center and Director of the Experimental Therapeutics at the Cleveland Clinic Cancer Center. He held the James Zito Chair in Cancer Research at the Taussig Cancer Center from 2001 to 2008.

[an error occurred while processing this directive]